Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Chem Commun (Camb)
; 56(61): 8683-8686, 2020 Aug 07.
Article
in English
| MEDLINE | ID: covidwho-622770
ABSTRACT
Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Recombinant Fusion Proteins
/
Viral Vaccines
/
Coronavirus Infections
/
Vaccines, Subunit
/
Pandemics
/
Spike Glycoprotein, Coronavirus
/
Betacoronavirus
/
Antibodies, Viral
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Chem Commun (Camb)
Journal subject:
Chemistry
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS